

# Implementation Status in the European Union



**MedDRA Users Group**  
**ICH 6 Osaka November 2003**


**Dr. Sabine Brosch (EMEA, UK)**

# Overview

- Background
- The European Pharmacovigilance System EudraVigilance
  - ◆ EudraVigilance Gateway
  - ◆ EudraVigilance Database Management System (DBMS)
  - ◆ Implementation Status of EMEA's partners
- Use of MedDRA
- EVWEB (EudraVigilance Web reporting tool)
- Next Steps
- Conclusions



# I. Background

- 
- EudraVigilance is
  - the European pharmacovigilance data-processing network and database management system for the exchange, processing and evaluation of Individual Case Safety Reports (ICSRs);
  - Operational since December 2001;
  - Fully compliant with the latest ICH E2B(M) and M2 standards and includes the M1 terminology, MedDRA.


## II.1 EudraVigilance Gateway

The EudraVigilance Gateway supports regulatory electronic submissions of Individual Case Safety Reports (ICSRs):


- ◆ First release in December 2001
- ◆ Upgraded version implemented in March 2003
- Total number of transactions in EV Test: 112.042
- Total number of transactions in EV Production: 86.634
- Total number of transactions: **198.676** (03 Nov. 01- 03 Oct.03)
- Statistic includes all safety and acknowledgement (ACK) messages and MDNs that were routed through the EV Gateway i.e. messages for the EMEA and re-routed messages for Competent Authorities.



# II.1 EV Gateway Transactions Safety & ACK Messages including MDNs




## II.2 EudraVigilance DBMS


- 
- European reference pharmacovigilance database, populated by importing and consolidating data from multiple sources, including information on medicinal products and adverse drug reactions;
  - Extensive query and tracking/tracing capability, both from a scientific and administrative business perspective;
  - Fully integrated organisation and user management and standard terminology;

EudraVigilance version 6.0 was released for test purposes on 1 March 2003 and was moved into production on 15 May 2003, replacing previous version 5.1.

## II.3 Implementation Status

- 
- In the time from January 2002 until 03 October 2003, 16 pharmaceutical companies and 3 National Competent Authorities started to report electronically to EudraVigilance.
  - Total number of cases received: 17.678
  - Total number of reports referring to these cases: 27.707 (incl. follow up reports, nullification reports, etc.)

# II.3.1 Pharmaceutical Companies



## Implementation Status of Pharmaceutical Companies

Company Name	Date of 1 <sup>st</sup> Submission	Parallel Reporting	None EU Reporting
Abbott	09 Jul 03	NONE	CAPs
BAYER	15 Aug 03	ALL	ALL
BMS	23 Sep 02	CAPs	CAPs
EISAI LTD	24 Feb 03	NONE	MRPs
Eli Lilly	23 Jul 03	NONE	CAPs
Gilead	25 Feb 03	CAPs	CAPs
GSK	02 Jul 03	NONE	CAPs
Lundbeck	10 Mar 03	MRPs,NAPs	MRPs,NAPs
MSD	10 Dec 02	NONE	ALL





## Implementation Status of Pharmaceutical Companies

Company Name	Date of 1 <sup>st</sup> Submission	Parallel Reporting	None EU Reporting
Novartis	21 Jul 03	CAPs	CAPs
NovoNordisk	03 Jun 03	ALL	ALL
PowderJect	10 Jul 03	NONE	CAPs
Procter & Gamble	02 May 03	MRPs, NAPs	MRPs, NAPs
Roche	24 Jan 03	ALL	ALL
Schering Plough	27 Jan 03	CAPs	CAPs
Wyeth	31 Jan 03	NONE	ALL



## II.3.1 Pharmaceutical Companies


*Number of cases and reports reported to the EMEA*

- Total number of cases received: 16.711
- Total number of reports referring to these cases: 21.203 (incl. follow up reports, nullification reports, etc.)

*Testing with the EMEA*

- 27 Companies are testing actively with the EMEA.
- Approximately 60 companies have declared interest to use EVWEB for reporting purposes.

# II.3.2 National Competent Authorities





## Implementation Status Competent Authorities

Authority Name	Date of 1 <sup>st</sup> Submission	EU Reporting
Danish Medicines Agency	05 Jul 02	ALL
INFARMED	14 Jan 02	CAPs
Norwegian Medicines Agency	27 May 03	CAPs

## II.3.2 National Competent Authorities

### *Number of cases and reports reported to the EMEA*

- Total number of cases received: 967
- Total number of reports referring to these cases: 1405 (incl. follow up reports, nullification reports, etc.)


### *Testing with the EMEA*

- 2 Competent Authorities
- BE, FI, GR, NL, SE intend to use EV System components at national level.

# III. Use of MedDRA

- MedDRA is used for coding an reporting purposes
  - ◆ At LLT level
  - ◆ Either as term (English) or numeric code
  - ◆ In the latest version (currently vs. 6.1)
  - ◆ For all E2B(M) applicable fields plus test names
  - ◆ For *27.707* reports, a total of 90.116 terms have been coded in MedDRA.

# Reported Terms (Top 10 SOC)



# III. Use of MedDRA

- For data evaluation and analysis MedDRA is used mainly
  - ◆ At PT level or a higher level in the hierarchy;
  - ◆ Normally in the latest version but the Eudra Vigilance System also permits the use of different MedDRA versions to compare results and to assess the potential impact on the outcome of the queries.

# IV. EVWEB



Online Access  
via the Internet

E  
U  
D  
R  
A  
V  
I  
G  
I  
L  
A  
N  
C  
E

- Use of EV Gateway & secure data transmission
- ICSR generation
- Message generation
- Message sending & receiving
- Access to complete MedDRA terminology
- Medicinal Product Dictionary
  - ✓ Access to complete data set
  - ✓ Update of products
  - ✓ Variation of products

# IV. EVWEB Low Revenue MedDRA Subscription

- Provides access to MedDRA within the EudraVigilance
- Intended for use by Small and Medium sized Enterprises (SMEs)
  - ◆ Using the EC's definition of SMEs
  - ◆ Available to small and micro sized enterprises

Enterprise category	Headcount	Turnover	Or	Balance sheet total
Small	< 50	≤ € 10 million		≤ € 10 million
Micro	< 10	≤ € 2 million		≤ € 2 million

# IV. EVWEB Low Revenue MedDRA Subscription

## ■ Qualification

- ◆ Meet the criteria for a definition of a small or micro enterprise as defined by the EC;
- ◆ Small or micro company must be located in the EEA or a EU Candidate Country.

## ■ Pricing

- ◆ \$1,000 per year or
- ◆ Free, if small/micro company submits 100 or fewer ICSRs per year directly to EMEA.

# IV. EVWEB Low Revenue MedDRA Subscription

## ■ Process

- ◆ Register with EudraVigilance
- ◆ Identify level of use
  - ◆ More than 100 ICSRs per year – contact MSSO for Low Revenue subscription (\$1,000)
  - ◆ 100 or fewer ICSRS per year – EMEA will grant access to MedDRA within EudraVigilance
- ◆ EMEA provides quarterly report to MSSO on reporting and use.

# V. Next Steps




- Implementation and testing of MedDRA SMQs (Standardised MedDRA Queries) as developed by the CIOMS/MedDRA MSSO Working Group;
- Electronic transmission of suspected, unexpected, serious adverse reactions (SUSARs) in the frame of clinical trials including the use of MedDRA by May 2004;
- EU enlargement (10 new Member States in May 2004);
- Focus on data analysis using new software tools;
- Continuation of implementation activities with EMEA's business partners.

# VI. Conclusions

The implementation of electronic transmission of ICSRs is:

- ◆ Making good progress;
- ◆ Is becoming more and more important taking into account the implementation of the electronic transmission of SUSARs, which is based on the same concepts,
- ◆ From EMEA's perspective a success.

## VI. Conclusions



The harmonization of pharmacovigilance reporting data elements and the medical terminology in the frame of ICH as well as their subsequent implementation at the level of EU regulators and pharmaceutical industry has proven as an important contribution to data standardization, a prerequisite for efficient and effective scientific data analysis at Community level and the the protection of public health.